Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial

This is a secondary analysis of a randomized controlled trial (RCT) on the effects of the glucagon-like peptide-1 receptor agonists exenatide and insulin aspartate 30 injection on carotid intima-media thickness. Here, we report the renal outcomes of the intervention in patients with type 2 diabetes...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative medicine 2022-10, Vol.70 (7), p.1529-1535
Main Authors: Zhang, Jie, Xian, Tong-Zhang, Wu, Ming-Xiao, Li, Chen, Wang, Weihao, Man, Fuli, Zhang, Xianbo, Wang, Xiaoxia, Pan, Qi, Guo, Lixin
Format: Article
Language:English
Subjects:
Antidiabetics
Blood pressure
Body mass index
Cholesterol
Clinical trials
Creatinine
Diabetes
GLP-1 receptor agonists
Glucagon
Glucose
Hemoglobin
High density lipoprotein
Inflammation
Insulin
Kidney diseases
Lipids
Lipoproteins
Metabolic disorders
Mortality
Obesity
Original research
Overweight
Oxidative stress
Peptides
Plasma
renal insufficiency
Statistical analysis
Weight control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is a secondary analysis of a randomized controlled trial (RCT) on the effects of the glucagon-like peptide-1 receptor agonists exenatide and insulin aspartate 30 injection on carotid intima-media thickness. Here, we report the renal outcomes of the intervention in patients with type 2 diabetes mellitus (T2DM). Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM. The primary end point was the change in the eGFR from baseline between the exenatide and insulin groups in normal versus overweight patients and patients with obesity. The secondary end point was the correlation between change in eGFR and oxidative stress, glycemic control, and dyslipidemia. There was a significant difference in eGFR between the insulin and exenatide groups at 52 weeks (p=0.0135). Within the insulin group, the eGFR remained below baseline at 52 weeks in all patients, and there was an increase in body weight in the normal group compared with the overweight patients and patients with obesity. The opposite was observed in the exenatide group. A decrease in body weight was prominent in the exenatide group at 52 weeks (p
ISSN:1081-5589
1708-8267
DOI:10.1136/jim-2021-002237